✦ LIBER ✦

2008 DOSE-RANGING, THREE-DAY MONOTHERAPY STUDY OF THE HCV NS3 PROTEASE INHIBITOR GS-9256

✍ Scribed by Lawitz, E.J.; Marbury, T.C.; Vince, B.D.; Grunenberg, N.; Rodriguez-Torres, M.; De Micco, M.P.; Tarro, J.N.; Shelton, M.J.; West, S.; Zong, J.; Bae, A.; Wong, K.; Mo, H.-M.; Oldach, D.; Delaney, W.; Rousseau, F.

Book ID: 123370129
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 71 KB
Volume: 52
Category: Article
ISSN: 0168-8278
DOI: 10.1016/S0168-8278(10)61199-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1219 THREE-DAY, DOSE-RANGING STUDY OF TH

1219 THREE-DAY, DOSE-RANGING STUDY OF THE HCV NS5A INHIBITOR GS-5885

✍ Lawitz, E.; Gruener, D.; Hill, J.; Marbury, T.; Komjathy, S.; DeMicco, M.; Muril 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 192 KB

779 PRECLINICAL CHARACTERIZATION OF THE

779 PRECLINICAL CHARACTERIZATION OF THE NOVEL HCV NS3 PROTEASE INHIBITOR GS-9256

✍ H. Yang; C. Yang; Y. Wang; G. Rhodes; M. Robinson; B. Schultz; O. Barauskas; B. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 37 KB

A phase 1, randomized, placebo-controlle

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C

✍ Eric J. Lawitz; Daniel Gruener; John M. Hill; Thomas Marbury; Lisa Moorehead; An 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 830 KB

1223 NO EARLY VIROLOGIC BREAKTHROUGH OBS

1223 NO EARLY VIROLOGIC BREAKTHROUGH OBSERVED WITH THE HCV NS3 PROTEASE INHIBITOR BMS-650032 IN MULTIPLE DOSE MONOTHERAPY STUDIES AND PHASE 2A COMBINATION STUDIES WITH PEGIFNα/RBV

✍ McPhee, F.; Sheaffer, A.; Yu, F.; Lee, M.; Chaniewski, S.; Falk, P.; Pasquinelli 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 41 KB